Related Experiment Video
Updated: Apr 15, 2026
09:56
Cochlear Implantation in the Guinea Pig
Published on: June 15, 2018
12.0K
Pirfenidone Reduces Intracochlear Fibrosis Caused by Cochlear Implantation in a Guinea Pig Model
Kady J Braack1,2, Kelly L Short2,3, Jorjina Plester2
1School of Human Sciences, University of Western Australia, Perth, WA 6009, Australia.
International Journal of Molecular Sciences
|April 14, 2026
Summary
Pirfenidone (PFD) effectively reduces cochlear implant-induced fibrosis by inhibiting key cellular processes and tissue reactions. This study highlights PFD as a promising therapeutic agent for improving outcomes in cochlear implant surgery.
Area of Science:
- Otolaryngology
- Regenerative Medicine
- Pharmacology
Background:
- Cochlear implants restore hearing but patient outcomes vary significantly.
- Cochlear fibrosis post-implantation is a key factor in outcome variability.
- Novel therapeutic strategies are needed to mitigate fibrosis.
Purpose of the Study:
- To investigate the anti-fibrotic potential of pirfenidone (PFD) against cochlear implant-induced fibrosis.
- To compare the efficacy of PFD with dexamethasone (DEX).
Main Methods:
- In vitro: PFD effects on fibrocyte signaling, proliferation, migration, and collagen III deposition.
- In vivo: Hydrogel-mediated PFD delivery in a guinea pig cochlear implant model.
- Tissue reaction quantified using micro-computed tomography.
Main Results:
- PFD significantly reduced p38 MAPK signaling, fibrocyte proliferation, migration, and collagen III deposition.
- In vivo, PFD reduced implant-induced tissue reaction by 40% (p=0.0297).
- DEX reduced tissue reaction by 36% (p=0.0436); PFD showed no ototoxicity.
Conclusions:
- Pirfenidone demonstrates significant therapeutic potential in preventing cochlear implant-associated fibrosis.
- PFD offers a promising, non-ototoxic approach to improve cochlear implant outcomes.
- Further research into PFD for otological applications is warranted.
